News & Analysis on Clinical Trial Services & Contract Research And Development
Now that the pharma industry and regulators have significant data on safety and efficacy of mRNA vaccines, many companies are looking beyond infectious disease to potentially develop therapies for a variety of indications. In this Q&A, a Catalent Biologics expert addresses the challenges of mRNA development and manufacturing, potential solutions & the future of mRNA in industry.
Paid for and content provided by Catalent
The nature and scope of clinical research has changed significantly over the past decade. Studies are more complex, globalized and patient-centric than ever. Yet, the processes used to package and ship study drugs to trial sites are stuck in an earlier...
With clinical study activity increasing across the Asia-Pacific region, it is important for sponsors—both in APAC and globally—to understand the broader area landscape in order to develop a distribution strategy that avoids delays and minimizes cost and...
The pharmaceutical industry had to adapt quickly to the pandemic if it was to continue to supply important medicines, while also racing to develop vaccines and treatments.
For more product information visit Catalent.